Reykjavik, Iceland & Dubai, United Arab Emirates — Alvotech (NASDAQ: ALVO) and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC, today announced that the Egyptian Drug Authority (EDA) has approved the manufacturing and distribution of AVT02 (adalimumab) a biosimilar for Humira®, which is commonly indicated for the treatment of rheumatoid arthritis and several...

Bioventure has extended its strategic partnership with Adalvo, the global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, by signing a licensing deal for four molecules, within the MENA region. The products are indicated in a variety of treatments including oncology, urinary tract infection, and anti-infective. With this collaboration, Adalvo is...

Alvotech (NASDAQ: ALVO) and Bioventure, announced that the Saudi Food & Drug Authority (“SFDA”) has approved the manufacturing and distribution of AVT02, a biosimilar for Humira® (adalimumab), which is commonly indicated for the treatment of rheumatoid arthritis and several other inflammatory diseases. The biosimilar will be marketed as Simlandi™ in Saudi Arabia. A biosimilar is...

Bioventure has partnered with Amman Pharmaceutical Industries, a leading pharmaceutical manufacturer with operations across the MENA region and other markets, to bring Aflibercept, a biosimilar of Bayer’s Eylea, to patients in the Levant region. The partnership grants Amman Pharma exclusive rights to register, hold marketing authorisation, and commercialise Aflibercept, which is developed and manufactured by...

Bioventure FZ-LLC and AJA Pharmaceuticals, a subsidiary of Saudi Chemical Company Holding (SCCH) signed a Memorandum of Understanding (MoU) to strengthen the existing strategic partnership between the two institutions. The collaboration will focus on diabetes, oncology and biosimilars, therapeutic categories that are forecasted to be among the largest and fastest-growing within the global pharma sector...